Bitcoin and Ethereum are shifting from traditional halving-driven cycles to a generational supercycle, driven by their growing role in mainstream finance and changing market structures. Key factors like the GENIUS Act, stablecoins, and tokenization are expanding crypto ownership beyond libertarian investors to broader portfolios. This transition mirrors past commodity supercycles, with increasing institutional interest concentrating around Bitcoin and Ethereum, potentially leading to rapid price gains and wider Wall Street participation. The market is still early in this evolution, with Bitcoin's technical outlook appearing strong.
Bitcoin's four-year cycle and supercycle shift are the story's focus, with Pluang market data as context. As of Oct 15, 2026 01:31 WIB, only 6 of 50 major cryptocurrencies rose. Notable moves include BAL up 11.14% at Rp16.297, EOS up 8.13% at Rp12.649, and SXP down 46.27% at Rp37, with typical hold times ranging from 85 to 94 days on Pluang.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
